-- 在Element Fleet Management (EFN.TO)公布第一季度财报前，加拿大帝国商业银行资本市场(CIBC Capital Markets)维持了对该股的“跑赢大盘”评级和41.00加元的目标价。 该行预计第一季度业绩将“稳健”。CIBC认为，如果贷款发放和贷款服务收入超出预期，“可能会恢复股价上涨势头”。 CIBC表示，其对第一季度每股收益0.34加元的预期与市场普遍预期一致，这意味着同比增长22%。该行还预测银团贷款收入将同比增长70%。 分析师Paul Holden表示：“我们维持‘跑赢大盘’评级，基于对2026年每股收益增长15%的预期以及目前市盈率不再过高的假设。由于EFN未能达到其2025年和2024年的贷款发放预期，我们预计市场将更加关注其贷款发放业务。” 该银行第一季度营收预计为3.14亿美元，同比增长14%。同时，该行预计第一季度支出同比增长7%，营业利润率为57.6%。
Price: $32.47, Change: $+0.13, Percent Change: +0.40%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.